口服孟鲁斯特、酮替芬加肌内注射卡介苗多糖核酸联合防治毛细支气管炎后哮喘的临床观察  

Montelukast,ketotifen combined with BCG-PSN decreased the incidence of asthma followig bronchiolitis

作　　者：郑达 黄建伟 陈小珊 

机构地区：[1]佛山市顺德区妇幼保健院儿科,广东省佛山528300

出　　处：《中国基层医药》2006年第5期813-814,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察口服孟鲁斯特和酮替芬加肌内注射卡介苗多糖核酸联合应用,能否降低毛细支气管炎后哮喘发病率。方法防治组(n=30)采用口服孟鲁斯特1个月,酮替芬3个月,肌注卡介苗多糖核酸6个月,临床随访>1年,检测患儿血清IgE、IgG、IgA、IgM的变化,统计发生哮喘的例数。31例毛细支气管炎患儿不用以上药物作为对照组。结果防治组患儿免疫功能改善明显,IgE水平下降,IgG、IgA水平升高。完成随访>1年者,防治组30例中有1例发生哮喘(3%),而对照组31例中有9例(29%)发生哮喘,两组差异有统计学意义(P<0.01)。结论口服孟鲁斯特、酮替芬加肌注卡介苗多糖核酸可降低毛细支气管炎后哮喘的患病率。Objective To evaluate the efficiency of montelukast and ketotifen combind with BCG-PSN （polysaccharide nucleic acid fraction of bacillus calmette guerin for injection） in decreasing the incidence of asthma following brochiolitis. Methods 30 patients with brochiolitis were given montelukast, ketotifen and BCG-PSN, compared with 31 patients with brochiolitis without the treatment. The total course were two months for oral montelukast,three months for oral ketotifen,and six months for injecting BCG-PSN. The time of follow up was over 1 year and the cases of patients developed asthma were investigated, serum level of IgE, IgA, IgG, IgM were tested before and after the treatment. Results After follow up 1 year, 1/30 （3 % ） of patents with brochiolitis receiving treatment developed asthma compared with 9/31 （29 % ） of the controls with brochiolitis（ P 〈 0.05 ）. The immune function of the patients with prevention and treatment obviously improved, the serum level of IgE decreased and IgA, IgG increased. Conclusion Montelukast and ketotifen combinded with BCG-PSN is an effective way to decrease the incidence of asthma following brochiolitis.

关 键 词：细支气管炎 哮喘 药物疗法 联合 小儿 

分 类 号：R725.6[医药卫生—儿科]